Physician profile
Angel Rodis
NPI 1417947094
$4,365.67
in general payments reported to CMS, 2019-2025
31 companies · $2,103 in 2025
The $2,103 reported for 2025 was more than what 87% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $153 · 2021: $40.86 · 2022: $339 · 2023: $240 · 2024: $1,218 · 2025: $2,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,463 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,463.07 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,066.09 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $764.38 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $280.05 | 2023-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $277.56 | 2023-2025 | |
| Genzyme Corporation | $221.35 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $205.38 | 2020-2025 | Aralast |
| Ani Pharmaceuticals, INC. | $148.92 | 2025 | Purified Cortrophin Gel |
| Verona Pharma, INC. | $146.66 | 2025 | Ohtuvayre |
| Harmony Biosciences LLC | $131.39 | 2024-2025 | |
| Pulmonx Corporation | $110.23 | 2022 | |
| Amgen INC. | $102.03 | 2023-2025 | Tezspire |
| Inari Medical, INC. | $101.03 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Insmed, INC. | $83.90 | 2019-2025 | Brinsupri, Arikayce |
| Vapotherm INC | $80.94 | 2019-2024 | Vapotherm |
| Grifols USA, LLC | $64.70 | 2019-2025 | Prolastin-C Liquid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $63.55 | 2025 | Zepbound |
| Genentech USA, INC. | $61.39 | 2019-2025 | Xolair |
| Philips North America LLC | $51.27 | 2020-2024 | (Ak6) Vest Therapy |
| Abbvie INC. | $49.91 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $45.83 | 2024-2025 | Opsumit, Uptravi |
| Avadel Cns Pharmaceuticals, LLC | $41.77 | 2024 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.46 | 2024 | Ofev |
| Novartis Pharmaceuticals Corporation | $40.13 | 2019 | |
| United Therapeutics Corporation | $36.61 | 2025 | Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $34.00 | 2024-2025 | |
| Boston Scientific Corporation | $23.60 | 2022 | |
| Ceribell, INC. | $22.33 | 2024 | Pocket Eeg Device |
| Baxter Healthcare | $19.64 | 2022 | |
| Circassia INC. | $18.08 | 2019 | |
| Nabriva Therapeutics, Plc | $17.11 | 2020 | |
| Axsome Therapeutics, INC. | $14.38 | 2024 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Rodis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.